FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

PMA: P980007 · Supplement: S005 · Decision Sep 10, 2004
Classifications
1
FEI Numbers
15
Registration Numbers
15

Basic Information

Device Name
Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions
Trade Name
ABBOTT AXSYM FREE PSA ASSAY
PMA Number
P980007
Supplement Number
S005
Device Class
FDA Class 3
Product Code
MTG
Generic Name
Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions
Medical Specialty
Unknown
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
September 10, 2004
Date Received
August 5, 2004
Supplement Type
Real-Time Process
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR THE ADDITION OF FLOMAX TO THE ANALYTICAL SPECIFICITY SECTION OF THE PACKAGE INSERT AND MINOR LABELING CHANGES TO THE ABBOTT AXSYM FREE PSA ASSAY FOR THE PURPOSE OF CLARIFICATION, UPDATES AND CONFORMATION TO REQUIREMENTS OF THE EUROPEAN COMMUNITY DIRECTIVES. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE SAME TRADE NAME AXSYM FREE PSA ASSAY AND IS INDICATED AS FOLLOWS: THE AXSYM FREE PSA ASSAY IS A MICROPARTICLE ENZYME IMMUNOASSAY (MEIA) FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE SPECIFIC ANTIGEN (PSA) IN HUMAN SERUM. THE AXSYM FREE PSA ASSAY IS INTENDED TO BE USED IN PSA VALUES BETWEEN 4 AND 10 NG/ML AND NON-SUSPICIOUS DRE TO DETERMINE THE % FREE PSA VALUE. THE AXSYM % FREE PSA VALUE CAN BE USED AS AN AID IN DISCRIMINATING BETWEEN PROSTATE CANCER AND BENIGN DISEASE.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MTG Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions